A new blood test may predict Alzheimer’s risk. It isn’t ready for prime time
A New Blood Test May Predict Alzheimer’s Risk Before Symptoms Appear
A new blood test may predict – Researchers have developed a promising blood marker that could help identify individuals at higher risk for Alzheimer’s disease years before cognitive decline becomes noticeable. The test measures p-tau217, a protein that accumulates in the brain as the condition progresses. According to recent findings, cognitively healthy older adults with elevated levels showed a 38% greater chance of early dementia indicators over five years, with that risk climbing to 78% over a decade, though the longer-term data remains less robust.
Understanding the Biological Mechanism
Traditional diagnostic methods rely heavily on expensive PET scans or invasive spinal taps to detect amyloid plaques and tau tangles in the brain. These proteins behave differently during disease progression. Amyloid plaques begin collecting decades before symptoms emerge, sometimes as early as a person’s thirties or forties. As amyloid levels rise, tau tangles gather inside cells, eventually triggering neuron death. Rachel Buckley, associate professor of neurology at Harvard Medical School, explained the relationship: “However, if an early stage of tau is combined with very elevated levels of amyloid, amyloid appears to be the match that lights the fire for the spread of disease across the brain.”
Buckley, who also works at Mass General Brigham Neuroscience Institute, added: “What we think the p-tau217 test can show us is the moment when amyloid is starting to cause this sort of wildfire.” Not everyone with high amyloid develops dementia, and tau levels alone don’t dictate cognitive impairment. Frontal lobe dementia represents a different pattern where tangles form without significant amyloid buildup.
Expert Recommendations and Limitations
Medical professionals caution that this test isn’t yet ready for widespread use among healthy populations. Dr. Richard Isaacson from the Institute for Neurodegenerative Diseases in Florida, who wasn’t involved in the study, emphasized the need for comprehensive evaluation. “Never would I order a p-tau217 test in isolation,” he noted. “For one, it tells you only one small part of what is most often a complicated biological picture.” He also warned that ordering a single test increases the chance of a less meaningful result, like a false positive. “If someone has a cold, if someone has kidney dysfunction, it can skew results,” Isaacson explained.
Isaacson views these tests as an “engine light” for treatment and lifestyle monitoring. “If you have one or two copies of APOE4 and APOE4 protein levels are high, you can put the right fuel in the car — nutrition, exercise, stress management and the rest — and do preventive maintenance to lower your proteins,” he said. The test is currently recommended more for people showing mild cognitive impairment or advanced dementia signs rather than the general healthy population.
Lifestyle interventions play a crucial role in managing risk. Laura Nisenbaum from the Alzheimer’s Drug Discovery Foundation highlighted the preventive potential: “Research is now showing up to 45% of dementia cases can be prevented with lifestyle interventions such as exercise, diet, social engagement, cognitive training, and management, vascular and metabolic risk factors,” she stated. She clarified that “The blood test, in and of itself, is not the diagnosis. Blood tests are used in combination with cognitive testing, for example, and ruling out other causes of the cognitive impairment.”
“The blood test, in and of itself, is not the diagnosis. Blood tests are used in combination with cognitive testing, for example, and ruling out other causes of the cognitive impairment.” — Laura Nisenbaum, Alzheimer’s Drug Discovery Foundation
While the research holds considerable promise, experts agree that this tool represents progress rather than a complete solution. The ultimate goal mirrors how we currently assess diabetes and heart attack risk—using accessible markers to guide early intervention and personalized care strategies for those most vulnerable to neurodegenerative conditions.